Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Androgen antagonists)
23,366 results
  • Cost-effectiveness analysis of androgen deprivation therapy with relugolix for the treatment of advanced prostate cancer. [Journal Article]
    J Am Pharm Assoc (2003). 2022 Dec 20 [Online ahead of print]Adekunle OA, Seoane-Vazquez E, Brown LM
  • CONCLUSIONS: Though the influence of adverse events was not considered in the analysis, ADT with relugolix was not a cost-effective choice for APC management. While the analysis revealed a slight chance of sustaining testosterone suppression with relugolix, ADT with relugolix provided no significant survival advantages over ADT with leuprolide. Therefore, this analysis confirms no need for further assessment of APC interventions to make informed decisions beneficial to the APC patients, oncologists, and other stakeholders.
  • Relugolix: A Review in Advanced Prostate Cancer. [Review]
    Target Oncol. 2023 Jan 18 [Online ahead of print]Shirley M
  • Relugolix (Orgovyx®), an orally active nonpeptide gonadotropin-releasing hormone (GnRH) receptor antagonist that provides rapid testosterone suppression, is indicated in the USA for the treatment of advanced prostate cancer and in the EU for advanced hormone-sensitive prostate cancer. In the pivotal phase III HERO trial in men with advanced prostate cancer, once-daily oral relugolix (with a loadi…
  • Mechanisms and targeting of proteosome-dependent androgen receptor degradation in prostate cancer. [Review]
    Am J Clin Exp Urol. 2022; 10(6):366-376.Fang Q, Cole RN, Wang Z
  • The androgen receptor (AR) remains to be a key target for the treatment of prostate cancer, including the majority of castration-resistant prostate cancer (CRPC). AR is stabilized in CRPC and the ubiquitin-proteasome system (UPS) plays a major role in AR degradation. Targeting AR for degradation provides a potential approach to overcome the resistance of CRPC to current AR antagonists, including …
  • Cytoreductive radical prostatectomy: who benefits from the surgical approach? [Review]
    Curr Opin Urol. 2023 Mar 01; 33(2):168-171.Heidenreich A, Paffenholz P, … Rieger C
  • CONCLUSIONS: From retrospective findings we have several clinical and basic science parameters to select patients for CRP. PSA at the time of surgery is the most frequently analyzed one, whereas CTC and HALP-score are promising tools to select patients that need to be validated.
  • Claudin-3 Loss of Expression Is a Prognostic Marker in Castration-Resistant Prostate Cancer. [Journal Article]
    Int J Mol Sci. 2023 Jan 02; 24(1)Orea MJ, Angulo JC, … Ropero S
  • Castration-resistant prostate cancer (CRPC) development is the foremost concern after treatment of patients with high risk with locally advanced or metastatic prostate cancer. Androgen receptor (AR) is the main driver of CRPC development, through its interaction with epigenetic modifier genes, placing epigenetics modifications in the forefront of CRPC development. Comparing the DNA methylation an…
New Search Next